Abbvie Inc Q3 2025 Earnings Analysis
Revenue grew 9.1% year over year and rose 2.3% sequentially. Margins weakened from the previous quarter, indicating ongoing pressure on profitability. Year-over-year earnings remained under pressure, showing that the recovery in profitability is still incomplete.
Revenue trend
Revenue growth stayed positive, supporting a healthier topline trend.
Margin and earnings quality
Margins deteriorated from last quarter, indicating weaker profit conversion.
What matters next
Investor focus is likely to remain on whether management can restore earnings momentum over coming quarters.
Revenue & YoY Growth
QuarterlyRevenue trend and year-over-year growth across recent reported quarterly periods.
Net Income & Net Margin
QuarterlyNet income and net margin trend over recent reported quarterly periods.
Revenue Analysis
Abbvie Inc reported $15.8B in revenue for Q3 2025, up 9.1% YoY and up 2.3% QoQ. Positive year-over-year growth suggests healthier revenue momentum.
Profitability Analysis
Net income came in at $186.0M, down 88.1% YoY and down 80.2% QoQ. Net margin was 1.2%. Sequential margin deterioration suggests profitability remains under pressure.
Frequently Asked Questions
Quick factual answers for this report. Need the why behind them? Ask the report assistant.
What was Abbvie Inc's revenue in Q3 2025?
Abbvie Inc reported revenue of $15.8B in Q3 2025.
What was Abbvie Inc's net income in Q3 2025?
Abbvie Inc reported net income of $186.0M in Q3 2025.
How did Abbvie Inc's revenue change year over year?
Abbvie Inc's revenue increased by 9.1% year over year in Q3 2025.
What was Abbvie Inc's net margin in Q3 2025?
Abbvie Inc's net margin was 1.2% in Q3 2025.
Compare this quarter with the previous earnings report.
Explore company profile, industry, and historical context.
View more quarterly financial trend pages for this company.
Data Source & Methodology
Financial data is sourced from company filings and internal processed earnings data.
YoY and QoQ values are derived from reported quarterly figures when not directly available.
This page is for informational purposes only and does not constitute investment advice.
